US-based biotechnology company Mind Medicine (MindMed) has dosed the first subject in the 52-week Phase III Voyage study of ...

Specific hypnotic techniques with the aid of subconscious resources can help patients improve or resolve their emetophobia ...

Almost three quarters of adolescents in Australia experience clinically significant depression or anxiety symptoms, with most being chronic, according to a new study. And preventive strategies outside ...

For the first time ever, researchers are administering LSD to patients in a Phase 3 clinical trial. The new study focuses on whether the psychedelic can be used to effectively treat generalized ...

Hormone therapy saves lives, but its hidden costs—sleepless nights, crippling anxiety, and intimacy struggles—leave breast ...

In animal studies, boosting serotonin in the cells that line the gut reduced anxious and depressive-like behaviors without causing cognitive or gastrointestinal side effects.

Research reveals new connections between the gut and brain, suggesting more targeted depression and anxiety treatments, and a ...

In past trials, ketamine intravenous treatment has shown promise, with 64% of depression patients in trials experiencing ...

Exposure therapy can help patients conquer their fears, but it isn’t effective for everyone. Researchers are exploring how ...

From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.

Between the two treatments, mindfulness-based stress reduction vs escitalopram, there were no clinically meaningful differences in their effects on anxiety.

A new study conducted as a collaboration between researchers from Dana-Farber Cancer Institute and Mass General Brigham explores whether cannabidiol (CBD), a component of marijuana, can reduce anxiety ...